- Home
- Clinical Trials
Respiratory Viruses Vaccine Studies Sydney DH 251
Respiratory Viruses Vaccine Study
Darlinghurst Sydney
Are you 60 to 83 years old and wanting to improve respiratory health?
You may be eligible to participate in a clinical research study testing an investigational vaccine against respiratory infections such as RSV, hMPV and Parainfluenza – three common viruses that can lead to serious illness in older adults.
Description
What to expect
Study details
Ages
60 to 83 years of age
Duration
The duration of the study is approximately 13 months including 6 scheduled clinic visits and 3 phone calls
Compensation
Eligible participants will be reimbursed
Eligibility Criteria
You may qualify for this study if you:
- Are aged 60 to 83 years
- Are a non-smoker or occasional smoker
- Are generally healthy or have well-controlled medical conditions
- Have not previously received an RSV vaccine
Other criteria apply. A study team will confirm your eligibility to participate in the trial
Locations
Description
RSV, hMPV and PIV3 are three highly contagious viruses that cause respiratory infections in people of all ages, but they are particularly dangerous for older adults, infants, and those with weakened immune systems. These viruses affect the lungs and airways, leading to symptoms like coughing, wheezing, shortness of breath, fatigue, and fever. While many recover fully, older adults are at greater risk for complications such as pneumonia and hospitalisation. These infections are highly prevalent and often go undiagnosed, impacting quality of life by limiting mobility, sleep, and independence. For many, even a mild illness can have lasting effects on health and wellbeing.
Currently, there are no widely available vaccines for hMPV or PIV3. While there are RSV vaccines available in Australia, it would be highly beneficial to have a vaccine that can target not only RSV but also hMPV and PIV3.
This study is evaluating an investigational combination vaccine against illness caused by RSV, hMPV and PIV3 in one injection. The study aims to evaluate if the vaccine will produce antibodies against the 3 viruses. The impact of this research may be life changing – not only improving individual health but also protecting vulnerable populations worldwide.
What to expect
Participants will be randomly assigned to either the investigational vaccine, a comparator vaccine, or a placebo (inactive substance) given as an intramuscular injection .
Each participant will receive one injection at the beginning of the study.
The injection is administered by our trained clinical staff during a scheduled visit to our clinic, and participants will be closely monitored afterward to ensure their safety.
Why join this clinical research study?
- Help develop a new vaccine to protect against serious respiratory infections
- Gain early access to new potential treatments at no cost
- Receive health checks and advice from our professional medical team
Apply now
Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.
Momentum Clinical Research AU is a member of the Global Site Holdings Group. Global Site Holdings Pty Limited ACN 668 977 062 trading as Momentum Clinical Research ABN 51 668 977 062 and our related entities (we, us, our), will use the Personal Information you have provided in the above form to review and respond to your enquiry, to contact you about any future trials or studies you may be eligible for, and otherwise in accordance with our Privacy Policy and as required and authorised by law. We may not be able to provide you with a complete response or a response at all to your enquiry if you do not provide the requested information. Our Privacy Policy also contains further information about how we collect, use, store or disclose your Personal Information, how you may seek access and correction of your Personal Information, and how you may make a complaint about a breach of privacy. If you have questions, please contact us at contact@momentumclinicalresearch.com.